Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment

Molecular Pharmaceutics

Volumn 12, Issue 11, 2015, Pages 3783-3791

  Sui, Xinbing ^a,b   Xu, Yinghua ^a   Wang, Xian ^a,b   Han, Weidong ^a,b   Pan, Hongming ^a,b   Xiao, Mang ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Key Laboratory of Biotherapy of Zhejiang Province   (China)

Author keywords

AMPK; cancer; metformin; prevention; therapy

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; DRUG RESPONSE; DRUG SCREENING; HUMAN; MOLECULAR BIOLOGY; NEOPLASM; PRIORITY JOURNAL; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84946414610     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00577     Document Type: Article

References (106)

1. Shaw, R. J.; Lamia, K. A.; Vasquez, D.; Koo, S. H.; Bardeesy, N.; Depinho, R. A.; Montminy, M.; Cantley, L. C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 2005, 310 (5754) 1642-1646 10.1126/science.1120781
2. Snima, K. S.; Pillai, P.; Cherian, A. M.; Nair, S. V.; Lakshmanan, V. K. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy Curr. Cancer Drug Targets 2014, 14 (8) 727-736 10.2174/1568009614666141020105502
3. Decensi, A.; Puntoni, M.; Goodwin, P.; Cazzaniga, M.; Gennari, A.; Bonanni, B.; Gandini, S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prev. Res. 2010, 3 (11) 1451-1461 10.1158/1940-6207.CAPR-10-0157
4. Rosilio, C.; Ben-Sahra, I.; Bost, F.; Peyron, J. F. Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia Cancer Lett. 2014, 346 (2) 188-196 10.1016/j.canlet.2014.01.006
5. Pernicova, I.; Korbonits, M. Metformin - mode of action and clinical implications for diabetes and cancer Nat. Rev. Endocrinol. 2014, 10 (3) 143-156 10.1038/nrendo.2013.256
6. Greenhill, C. Gastric cancer: Metformin improves survival and recurrence rate in patients with diabetes and gastric cancer Nat. Rev. Gastroenterol. Hepatol. 2015, 12 (3) 124 10.1038/nrgastro.2015.9
7. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update Nat. Rev. Cancer 2012, 12 (3) 159-169 10.1038/nrc3215
8. Martin-Castillo, B.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Menendez, J. A. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena Cell Cycle 2010, 9 (6) 1057-1064 10.4161/cc.9.6.10994
9. Luengo, A.; Sullivan, L. B.; Heiden, M. G. Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy BMC Biol. 2014, 12, 82 10.1186/s12915-014-0082-4
10. Evans, J. M.; Donnelly, L. A.; Emslie-Smith, A. M.; Alessi, D. R.; Morris, A. D. Metformin and reduced risk of cancer in diabetic patients BMJ 2005, 330 (7503) 1304-1305 10.1136/bmj.38415.708634.F7
11. Morales, D. R.; Morris, A. D. Metformin in cancer treatment and prevention Annu. Rev. Med. 2015, 66, 17-29 10.1146/annurev-med-062613-093128
12. Tseng, C. H. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus Eur. J. Cancer 2014, 50 (16) 2831-2837 10.1016/j.ejca.2014.08.007
13. Thakkar, B.; Aronis, K. N.; Vamvini, M. T.; Shields, K.; Mantzoros, C. S. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies Metab., Clin. Exp. 2013, 62 (7) 922-934 10.1016/j.metabol.2013.01.014
14. Lin, H. C.; Kachingwe, B. H.; Lin, H. L.; Cheng, H. W.; Uang, Y. S.; Wang, L. H. Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study Pharmacotherapy 2014, 34 (1) 36-45 10.1002/phar.1334
15. Gandini, S.; Puntoni, M.; Heckman-Stoddard, B. M.; Dunn, B. K.; Ford, L.; DeCensi, A.; Szabo, E. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders Cancer Prev. Res. 2014, 7 (9) 867-885 10.1158/1940-6207.CAPR-13-0424
16. Sui, X.; Xu, Y.; Yang, J.; Fang, Y.; Lou, H.; Han, W.; Zhang, M.; Chen, W.; Wang, K.; Li, D.; Jin, W.; Lou, F.; Zheng, Y.; Hu, H.; Gong, L.; Zhou, X.; Pan, Q.; Pan, H.; Wang, X.; He, C. Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation PLoS One 2014, 9 (5) e97781 10.1371/journal.pone.0097781
17. Thompson, M. D.; Grubbs, C. J.; Bode, A. M.; Reid, J. M.; McGovern, R.; Bernard, P. S.; Stijleman, I. J.; Green, J. E.; Bennett, C.; Juliana, M. M.; Moeinpour, F.; Steele, V. E.; Lubet, R. A. Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models Cancer Prev. Res. 2015, 8 (3) 231-239 10.1158/1940-6207.CAPR-14-0181-T
18. Bodmer, M.; Becker, C.; Jick, S. S.; Meier, C. R. Metformin does not alter the risk of lung cancer: a case-control analysis Lung cancer 2012, 78 (2) 133-137 10.1016/j.lungcan.2012.08.010
19. Bodmer, M.; Becker, C.; Meier, C.; Jick, S. S.; Meier, C. R. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis Cancer Epidemiol., Biomarkers Prev. 2012, 21 (2) 280-286 10.1158/1055-9965.EPI-11-0992-T
20. Anandakumar, P.; Kamaraj, S.; Jagan, S.; Ramakrishnan, G.; Devaki, T. Effect of capsaicin on glucose metabolism studied in experimental lung carcinogenesis Nat. Prod. Res. 2009, 23 (8) 763-774 10.1080/14786410802604571
21. Nakamura, A.; Tajima, K.; Zolzaya, K.; Sato, K.; Inoue, R.; Yoneda, M.; Fujita, K.; Nozaki, Y.; Kubota, K. C.; Haga, H.; Kubota, N.; Nagashima, Y.; Nakajima, A.; Maeda, S.; Kadowaki, T.; Terauchi, Y. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance Diabetologia 2012, 55 (12) 3382-3391 10.1007/s00125-012-2703-1
22. Algire, C.; Amrein, L.; Zakikhani, M.; Panasci, L.; Pollak, M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase Endocr.-Relat. Cancer 2010, 17 (2) 351-360 10.1677/ERC-09-0252
23. Renehan, A. G.; Harvie, M.; Howell, A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on Endocr.-Relat. Cancer 2006, 13 (2) 273-278 10.1677/erc.1.01219
24. Halje, M.; Nordin, M.; Bergman, D.; Engstrom, W. The effect of insulin-like growth factor II in the regulation of tumour cell growth in vitro and tumorigenesis in vivo In vivo 2012, 26 (4) 519-526
25. Hung, P. S.; Kao, S. Y.; Shih, Y. H.; Chiou, S. H.; Liu, C. J.; Chang, K. W.; Lin, S. C. Insulin-like growth factor binding protein-5 (IGFBP-5) suppresses the tumourigenesis of head and neck squamous cell carcinoma Journal of pathology 2008, 214 (3) 368-376 10.1002/path.2280
26. Sui, X.; Chen, R.; Wang, Z.; Huang, Z.; Kong, N.; Zhang, M.; Han, W.; Lou, F.; Yang, J.; Zhang, Q.; Wang, X.; He, C.; Pan, H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment Cell Death Dis. 2013, 4, e838 10.1038/cddis.2013.350
27. Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; Turk, B. E.; Shaw, R. J. AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol. Cell 2008, 30 (2) 214-226 10.1016/j.molcel.2008.03.003
28. Tripathi, D. N.; Chowdhury, R.; Trudel, L. J.; Tee, A. R.; Slack, R. S.; Walker, C. L.; Wogan, G. N. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1 Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (32) E2950-2957 10.1073/pnas.1307736110
29. Han, G.; Gong, H.; Wang, Y.; Guo, S.; Liu, K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell Cancer Biol. Ther. 2015, 16 (1) 77-87 10.4161/15384047.2014.987021
30. Leclerc, G. M.; Leclerc, G. J.; Kuznetsov, J. N.; DeSalvo, J.; Barredo, J. C. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts PLoS One 2013, 8 (8) e74420 10.1371/journal.pone.0074420
31. Zheng, L.; Yang, W.; Wu, F.; Wang, C.; Yu, L.; Tang, L.; Qiu, B.; Li, Y.; Guo, L.; Wu, M.; Feng, G.; Zou, D.; Wang, H. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma Clin. Cancer Res. 2013, 19 (19) 5372-5380 10.1158/1078-0432.CCR-13-0203
32. Nair, V.; Sreevalsan, S.; Basha, R.; Abdelrahim, M.; Abudayyeh, A.; Rodrigues Hoffman, A.; Safe, S. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors J. Biol. Chem. 2014, 289 (40) 27692-2701 10.1074/jbc.M114.592576
33. Malki, A.; Youssef, A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling Oncol. Res. 2011, 19 (6) 275-285 10.3727/096504011X13021877989838
34. Demir, U.; Koehler, A.; Schneider, R.; Schweiger, S.; Klocker, H. Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells BMC Cancer 2014, 14, 52 10.1186/1471-2407-14-52
35. Lee, S. Y.; Song, C. H.; Xie, Y. B.; Jung, C.; Choi, H. S.; Lee, K. SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells Cancer Lett. 2014, 354 (2) 390-397 10.1016/j.canlet.2014.09.001
36. Scotland, S.; Saland, E.; Skuli, N.; de Toni, F.; Boutzen, H.; Micklow, E.; Senegas, I.; Peyraud, R.; Peyriga, L.; Theodoro, F.; Dumon, E.; Martineau, Y.; Danet-Desnoyers, G.; Bono, F.; Rocher, C.; Levade, T.; Manenti, S.; Junot, C.; Portais, J. C.; Alet, N.; Recher, C.; Selak, M. A.; Carroll, M.; Sarry, J. E. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells Leukemia 2013, 27 (11) 2129-2138 10.1038/leu.2013.107
37. Nair, V.; Pathi, S.; Jutooru, I.; Sreevalsan, S.; Basha, R.; Abdelrahim, M.; Samudio, I.; Safe, S. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors Carcinogenesis 2013, 34 (12) 2870-2879 10.1093/carcin/bgt231
38. Kondo, Y.; Kanzawa, T.; Sawaya, R.; Kondo, S. The role of autophagy in cancer development and response to therapy Nat. Rev. Cancer 2005, 5 (9) 726-734 10.1038/nrc1692
39. Janku, F.; McConkey, D. J.; Hong, D. S.; Kurzrock, R. Autophagy as a target for anticancer therapy Nat. Rev. Clin. Oncol. 2011, 8 (9) 528-539 10.1038/nrclinonc.2011.71
40. Buzzai, M.; Jones, R. G.; Amaravadi, R. K.; Lum, J. J.; DeBerardinis, R. J.; Zhao, F.; Viollet, B.; Thompson, C. B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res. 2007, 67 (14) 6745-6752 10.1158/0008-5472.CAN-06-4447
41. Moon, H. S.; Kim, B.; Gwak, H.; Suh, D. H.; Song, Y. S. Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2alpha) pathway protect ovarian cancer cells from metformin-induced apoptosis Mol. Carcinog. 2015, n/a 10.1002/mc.22284
42. Feng, Y.; Ke, C.; Tang, Q.; Dong, H.; Zheng, X.; Lin, W.; Ke, J.; Huang, J.; Yeung, S. C.; Zhang, H. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling Cell Death Dis. 2014, 5, e1088 10.1038/cddis.2014.59
43. Shi, W. Y.; Xiao, D.; Wang, L.; Dong, L. H.; Yan, Z. X.; Shen, Z. X.; Chen, S. J.; Chen, Y.; Zhao, W. L. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy Cell Death Dis. 2012, 3, e275 10.1038/cddis.2012.13
44. Tomic, T.; Botton, T.; Cerezo, M.; Robert, G.; Luciano, F.; Puissant, A.; Gounon, P.; Allegra, M.; Bertolotto, C.; Bereder, J. M.; Tartare-Deckert, S.; Bahadoran, P.; Auberger, P.; Ballotti, R.; Rocchi, S. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms Cell Death Dis. 2011, 2, e199 10.1038/cddis.2011.86
45. Brodowska, K.; Theodoropoulou, S.; Meyer Zu Horste, M.; Paschalis, E. I.; Takeuchi, K.; Scott, G.; Ramsey, D. J.; Kiernan, E.; Hoang, M.; Cichy, J.; Miller, J. W.; Gragoudas, E. S.; Vavvas, D. G. Effects of metformin on retinoblastoma growth in vitro and in vivo Int. J. Oncol. 2014, 45 (6) 2311-2324 10.3892/ijo.2014.2650
46. Takahashi, A.; Kimura, F.; Yamanaka, A.; Takebayashi, A.; Kita, N.; Takahashi, K.; Murakami, T. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis Cancer Cell Int. 2014, 14, 53 10.1186/1475-2867-14-53
47. Xiao, X.; He, Q.; Lu, C.; Werle, K. D.; Zhao, R. X.; Chen, J.; Davis, B. C.; Cui, R.; Liang, J.; Xu, Z. X. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells Gynecol. Oncol. 2012, 127 (1) 249-255 10.1016/j.ygyno.2012.06.032
48. Jagannathan, S.; Abdel-Malek, M. A.; Malek, E.; Vad, N.; Latif, T.; Anderson, K. C.; Driscoll, J. J. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib Leukemia 2015, 10.1038/leu.2015.157
49. Duo, J.; Ma, Y.; Wang, G.; Han, X.; Zhang, C. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line DNA Cell Biol. 2013, 32 (4) 156-164 10.1089/dna.2012.1926
50. Zhang, T.; Wang, X.; He, D.; Jin, X.; Guo, P. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP Anti-Cancer Drugs 2014, 25 (8) 887-897 10.1097/CAD.0000000000000116
51. Kitazono, S.; Takiguchi, Y.; Ashinuma, H.; Saito-Kitazono, M.; Kitamura, A.; Chiba, T.; Sakaida, E.; Sekine, I.; Tada, Y.; Kurosu, K.; Sakao, S.; Tanabe, N.; Iwama, A.; Yokosuka, O.; Tatsumi, K. Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line Int. J. Oncol. 2013, 43 (6) 1846-1854 10.3892/ijo.2013.2120
52. Oxnard, G. R.; Arcila, M. E.; Chmielecki, J.; Ladanyi, M.; Miller, V. A.; Pao, W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer Clin. Cancer Res. 2011, 17 (17) 5530-5537 10.1158/1078-0432.CCR-10-2571
53. Cha, Y. K.; Lee, H. Y.; Ahn, M. J.; Choi, Y. L.; Lee, J. H.; Park, K.; Lee, K. S. Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy Clin. Lung Cancer 2015, 16 (3) 228-236 10.1016/j.cllc.2014.11.002
54. Li, L.; Han, R.; Xiao, H.; Lin, C.; Wang, Y.; Liu, H.; Li, K.; Chen, H.; Sun, F.; Yang, Z.; Jiang, J.; He, Y. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal Clin. Cancer Res. 2014, 20 (10) 2714-2726 10.1158/1078-0432.CCR-13-2613
55. Lin, C. C.; Yeh, H. H.; Huang, W. L.; Yan, J. J.; Lai, W. W.; Su, W. P.; Chen, H. H.; Su, W. C. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway Am. J. Respir. Cell Mol. Biol. 2013, 49 (2) 241-250 10.1165/rcmb.2012-0244OC
56. Baron, B.; Wang, Y.; Maehara, S.; Maehara, Y.; Kuramitsu, Y.; Nakamura, K. Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action Anticancer research 2015, 35 (4) 1941-1949
57. Vujic, I.; Sanlorenzo, M.; Posch, C.; Esteve-Puig, R.; Yen, A. J.; Kwong, A.; Tsumura, A.; Murphy, R.; Rappersberger, K.; Ortiz-Urda, S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer Oncotarget 2015, 6 (2) 969-978 10.18632/oncotarget.2824
58. Ling, S.; Tian, Y.; Zhang, H.; Jia, K.; Feng, T.; Sun, D.; Gao, Z.; Xu, F.; Hou, Z.; Li, Y.; Wang, L. Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel7402/5fluorouracil cells Mol. Med. Rep. 2014, 10 (6) 2891-2897 10.3892/mmr.2014.2614
59. Hartwell, L. H.; Kastan, M. B. Cell cycle control and cancer Science 1994, 266 (5192) 1821-1828 10.1126/science.7997877
60. Dickson, M. A.; Schwartz, G. K. Development of cell-cycle inhibitors for cancer therapy Current oncology 2009, 16 (2) 36-43 10.3747/co.v16i2.428
61. Miyoshi, H.; Kato, K.; Iwama, H.; Maeda, E.; Sakamoto, T.; Fujita, K.; Toyota, Y.; Tani, J.; Nomura, T.; Mimura, S.; Kobayashi, M.; Morishita, A.; Kobara, H.; Mori, H.; Yoneyama, H.; Deguchi, A.; Himoto, T.; Kurokohchi, K.; Okano, K.; Suzuki, Y.; Murao, K.; Masaki, T. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo Int. J. Oncol. 2014, 45 (1) 322-332 10.3892/ijo.2014.2419
62. Chen, H. P.; Shieh, J. J.; Chang, C. C.; Chen, T. T.; Lin, J. T.; Wu, M. S.; Lin, J. H.; Wu, C. Y. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies Gut 2013, 62 (4) 606-615 10.1136/gutjnl-2011-301708
63. Queiroz, E. A.; Puukila, S.; Eichler, R.; Sampaio, S. C.; Forsyth, H. L.; Lees, S. J.; Barbosa, A. M.; Dekker, R. F.; Fortes, Z. B.; Khaper, N. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells PLoS One 2014, 9 (5) e98207 10.1371/journal.pone.0098207
64. Ben Sahra, I.; Regazzetti, C.; Robert, G.; Laurent, K.; Le Marchand-Brustel, Y.; Auberger, P.; Tanti, J. F.; Giorgetti-Peraldi, S.; Bost, F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1 Cancer Res. 2011, 71 (13) 4366-4372 10.1158/0008-5472.CAN-10-1769
65. Babcook, M. A.; Sramkoski, R. M.; Fujioka, H.; Daneshgari, F.; Almasan, A.; Shukla, S.; Nanavaty, R. R.; Gupta, S. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells Cell Death Dis. 2014, 5, e1536 10.1038/cddis.2014.500
66. Cantoria, M. J.; Boros, L. G.; Meuillet, E. J. Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells Metabolomics 2014, 10 (1) 91-104 10.1007/s11306-013-0555-4
67. Marini, C.; Salani, B.; Massollo, M.; Amaro, A.; Esposito, A. I.; Orengo, A. M.; Capitanio, S.; Emionite, L.; Riondato, M.; Bottoni, G.; Massara, C.; Boccardo, S.; Fabbi, M.; Campi, C.; Ravera, S.; Angelini, G.; Morbelli, S.; Cilli, M.; Cordera, R.; Truini, M.; Maggi, D.; Pfeffer, U.; Sambuceti, G. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer Cell Cycle 2013, 12 (22) 3490-3499 10.4161/cc.26461
68. Fendt, S. M.; Bell, E. L.; Keibler, M. A.; Davidson, S. M.; Wirth, G. J.; Fiske, B.; Mayers, J. R.; Schwab, M.; Bellinger, G.; Csibi, A.; Patnaik, A.; Blouin, M. J.; Cantley, L. C.; Guarente, L.; Blenis, J.; Pollak, M. N.; Olumi, A. F.; Vander Heiden, M. G.; Stephanopoulos, G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism Cancer Res. 2013, 73 (14) 4429-4438 10.1158/0008-5472.CAN-13-0080
69. Sinnett-Smith, J.; Kisfalvi, K.; Kui, R.; Rozengurt, E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK Biochem. Biophys. Res. Commun. 2013, 430 (1) 352-357 10.1016/j.bbrc.2012.11.010
70. Zordoky, B. N.; Bark, D.; Soltys, C. L.; Sung, M. M.; Dyck, J. R. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention Biochim. Biophys. Acta, Gen. Subj. 2014, 1840 (6) 1943-1957 10.1016/j.bbagen.2014.01.023
71. Menendez, J. A.; Oliveras-Ferraros, C.; Cufi, S.; Corominas-Faja, B.; Joven, J.; Martin-Castillo, B.; Vazquez-Martin, A. Metformin is synthetically lethal with glucose withdrawal in cancer cells Cell Cycle 2012, 11 (15) 2782-2792 10.4161/cc.20948
72. Thiery, J. P.; Acloque, H.; Huang, R. Y.; Nieto, M. A. Epithelial-mesenchymal transitions in development and disease Cell 2009, 139 (5) 871-890 10.1016/j.cell.2009.11.007
73. Iwatsuki, M.; Mimori, K.; Yokobori, T.; Ishi, H.; Beppu, T.; Nakamori, S.; Baba, H.; Mori, M. Epithelial-mesenchymal transition in cancer development and its clinical significance Cancer Sci. 2010, 101 (2) 293-299 10.1111/j.1349-7006.2009.01419.x
74. Cufi, S.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Martin-Castillo, B.; Joven, J.; Menendez, J. A. Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis Cell Cycle 2010, 9 (22) 4461-4468 10.4161/cc.9.22.14048
75. Qu, C.; Zhang, W.; Zheng, G.; Zhang, Z.; Yin, J.; He, Z. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells Mol. Cell. Biochem. 2014, 386 (1-2) 63-71 10.1007/s11010-013-1845-x
76. Zhao, Z.; Cheng, X.; Wang, Y.; Han, R.; Li, L.; Xiang, T.; He, L.; Long, H.; Zhu, B.; He, Y. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis PLoS One 2014, 9 (4) e95884 10.1371/journal.pone.0095884
77. Zhang, J.; Shen, C.; Wang, L.; Ma, Q.; Xia, P.; Qi, M.; Yang, M.; Han, B. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4 Biochem. Biophys. Res. Commun. 2014, 452 (3) 746-752 10.1016/j.bbrc.2014.08.154
78. Aravinthan, A. Cellular senescence: a hitchhiker's guide Hum. Cell 2015, 28 (2) 51-64 10.1007/s13577-015-0110-x
79. Moiseeva, O.; Deschenes-Simard, X.; Pollak, M.; Ferbeyre, G. Metformin, aging and cancer Aging 2013, 5 (5) 330-331
80. Moiseeva, O.; Deschenes-Simard, X.; St-Germain, E.; Igelmann, S.; Huot, G.; Cadar, A. E.; Bourdeau, V.; Pollak, M. N.; Ferbeyre, G. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation Aging Cell 2013, 12 (3) 489-498 10.1111/acel.12075
81. Williams, C. C.; Singleton, B. A.; Llopis, S. D.; Skripnikova, E. V. Metformin induces a senescence-associated gene signature in breast cancer cells Journal of Health Care for the Poor and Underserved 2013, 24 (1 Suppl) 93-103 10.1353/hpu.2013.0044
82. Yi, G.; He, Z.; Zhou, X.; Xian, L.; Yuan, T.; Jia, X.; Hong, J.; He, L.; Liu, J. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway Int. J. Oncol. 2013, 43 (5) 1503-1510 10.3892/ijo.2013.2077
83. Arunachalam, G.; Samuel, S. M.; Marei, I.; Ding, H.; Triggle, C. R. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1 British journal of pharmacology 2014, 171 (2) 523-535 10.1111/bph.12496
84. Hirsch, H. A.; Iliopoulos, D.; Tsichlis, P. N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res. 2009, 69 (19) 7507-7511 10.1158/0008-5472.CAN-09-2994
85. Yang, Q.; Zhang, T.; Wang, C.; Jiao, J.; Li, J.; Deng, Y. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells Eur. J. Pharm. Biopharm. 2014, 88 (3) 737-745 10.1016/j.ejpb.2014.10.006
86. Xiao, Z.; Sperl, B.; Ullrich, A.; Knyazev, P. Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status Oncotarget 201, 5 (24) 12877-12890
87. Kim, T. H.; Suh, D. H.; Kim, M. K.; Song, Y. S. Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer BioMed Res. Int. 2014, 2014, 132702 10.1155/2014/132702
88. Oliveras-Ferraros, C.; Cufi, S.; Vazquez-Martin, A.; Menendez, O. J.; Bosch-Barrera, J.; Martin-Castillo, B.; Joven, J.; Menendez, J. A. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation Cell Cycle 2012, 11 (5) 865-870 10.4161/cc.11.5.19252
89. Eikawa, S.; Nishida, M.; Mizukami, S.; Yamazaki, C.; Nakayama, E.; Udono, H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin Proc. Natl. Acad. Sci. U. S. A. 2015, 112 (6) 1809-1814 10.1073/pnas.1417636112
90. Son, H. J.; Lee, J.; Lee, S. Y.; Kim, E. K.; Park, M. J.; Kim, K. W.; Park, S. H.; Cho, M. L. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis Mediators Inflammation 2014, 2014, 973986 10.1155/2014/973986
91. Dworacki, G.; Urazayev, O.; Bekmukhambetov, Y.; Iskakova, S.; Frycz, B. A.; Jagodzinski, P. P.; Dworacka, M. Thymic emigration patterns in type 2 diabetic patients treated with metformin Immunology 2015, n/a 10.1111/imm.12522
92. Zhao, D.; Long, X. D.; Lu, T. F.; Wang, T.; Zhang, W. W.; Liu, Y. X.; Cui, X. L.; Dai, H. J.; Xue, F.; Xia, Q. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma Int. J. Cancer 2015, 136 (11) 2556-2565 10.1002/ijc.29305
93. Zarrouk, M.; Finlay, D. K.; Foretz, M.; Viollet, B.; Cantrell, D. A. Adenosine-mono-phosphate-activated protein kinase-independent effects of metformin in T cells PLoS One 2014, 9 (9) e106710 10.1371/journal.pone.0106710
94. Algire, C.; Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.; Pollak, M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo Oncogene 2011, 30 (10) 1174-1182 10.1038/onc.2010.483
95. Shackelford, D. B.; Abt, E.; Gerken, L.; Vasquez, D. S.; Seki, A.; Leblanc, M.; Wei, L.; Fishbein, M. C.; Czernin, J.; Mischel, P. S.; Shaw, R. J. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin Cancer Cell 2013, 23 (2) 143-158 10.1016/j.ccr.2012.12.008
96. Sandulache, V. C.; Skinner, H. D.; Ow, T. J.; Zhang, A.; Xia, X.; Luchak, J. M.; Wong, L. J.; Pickering, C. R.; Zhou, G.; Myers, J. N. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status Cancer 2012, 118 (3) 711-721 10.1002/cncr.26321
97. Iglesias, D. A.; Yates, M. S.; van der Hoeven, D.; Rodkey, T. L.; Zhang, Q.; Co, N. N.; Burzawa, J.; Chigurupati, S.; Celestino, J.; Bowser, J.; Broaddus, R.; Hancock, J. F.; Schmandt, R.; Lu, K. H. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy Mol. Cancer Ther. 2013, 12 (12) 2847-2856 10.1158/1535-7163.MCT-13-0439
98. Ma, Y.; Guo, F. C.; Wang, W.; Shi, H. S.; Li, D.; Wang, Y. S. Kras gene mutation as a predictor of cancer cell responsiveness to metformin Mol. Med. Rep. 2013, 8 (3) 763-768 10.3892/mmr.2013.1596
99. Cufi, S.; Corominas-Faja, B.; Lopez-Bonet, E.; Bonavia, R.; Pernas, S.; Lopez, I. A.; Dorca, J.; Martinez, S.; Lopez, N. B.; Fernandez, S. D.; Cuyas, E.; Visa, J.; Rodriguez-Gallego, E.; Quirantes-Pine, R.; Segura-Carretero, A.; Joven, J.; Martin-Castillo, B.; Menendez, J. A. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin Oncotarget 2013, 4 (9) 1484-1495 10.18632/oncotarget.1234
100. Jalving, M.; Gietema, J. A.; Lefrandt, J. D.; de Jong, S.; Reyners, A. K.; Gans, R. O.; de Vries, E. G. Metformin: taking away the candy for cancer? Eur. J. Cancer 2010, 46 (13) 2369-2380 10.1016/j.ejca.2010.06.012
101. Hosono, K.; Endo, H.; Takahashi, H.; Sugiyama, M.; Sakai, E.; Uchiyama, T.; Suzuki, K.; Iida, H.; Sakamoto, Y.; Yoneda, K.; Koide, T.; Tokoro, C.; Abe, Y.; Inamori, M.; Nakagama, H.; Nakajima, A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev. Res. 2010, 3 (9) 1077-1083 10.1158/1940-6207.CAPR-10-0186
102. Joshua, A. M.; Zannella, V. E.; Downes, M. R.; Bowes, B.; Hersey, K.; Koritzinsky, M.; Schwab, M.; Hofmann, U.; Evans, A.; van der Kwast, T.; Trachtenberg, J.; Finelli, A.; Fleshner, N.; Sweet, J.; Pollak, M. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer Prostate Cancer Prostatic Dis. 2014, 17 (3) 252-258 10.1038/pcan.2014.20
103. Snima, K. S.; Jayakumar, R.; Lakshmanan, V. K. In vitro and in vivo biological evaluation of O-carboxymethyl chitosan encapsulated metformin nanoparticles for pancreatic cancer therapy Pharm. Res. 2014, 31 (12) 3361-3370 10.1007/s11095-014-1425-0
104. Snima, K. S.; Nair, R. S.; Nair, S. V.; Kamath, C. R.; Lakshmanan, V. K. Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy J. Biomed. Nanotechnol. 2015, 11 (1) 93-104 10.1166/jbn.2015.1877
105. Dowling, R. J.; Niraula, S.; Stambolic, V.; Goodwin, P. J. Metformin in cancer: translational challenges J. Mol. Endocrinol. 2012, 48 (3) R31-43 10.1530/JME-12-0007
106. Pawlyk, A. C.; Giacomini, K. M.; McKeon, C.; Shuldiner, A. R.; Florez, J. C. Metformin pharmacogenomics: current status and future directions Diabetes 2014, 63 (8) 2590-2599 10.2337/db13-1367